Future clinical potential of oncolytic virotherapy for pediatric CNS tumors.

摘要: 307 ISSN 2045-0907 10.2217/CNS.13.25 © 2013 Future Medicine Ltd CNS Oncol. (2013) 2(4), 307–310 tumors are the most common solid of childhood [1]. Although treatment advances have improved survival for some pediatric diseases, there unfortunately remains a group associated with signif icantly poorer prognosis. Among these high-grade gliomas (HGGs), which, despite aggressive manage ment, usually recur and 5-year outcomes between 15 35% [2]. Diffuse intrinsic pontine glioma (DIPG), highly malignant brainstem tumor median less than 1 year [3], constant therapeutic challenge. High-risk metastatic medulloblastoma cerebrospinal fluid dissemination at presentation is rates 40 70% intensive regimens [4]. In addition, rare malignancies, such as atypical teratoid rhabdoid tumors, although often demonstrating response to chemotherapy, early relapse only 17 months [5]. Oncolytic virotherapy, which uses viruses selectively infect destroy cancer cells [6], offers novel approach poor prognosis tumors. While extensive literature on oncolytic virotherapy adult brain HGG, work currently just gathering steam. With no open clinical trials focused in we can draw upon available preclinical models, alongside limited data, progress exciting future potential this modality. The majority studies evaluate eff icacy medulloblastoma. Over years ago, Lasner et al. published that herpes simplex virus (HSV) variant 1716 could D283 demonstrated intratumoral injection into tumor-bearing mice conferred statistically significant increase compared control murine models [7]. Pyles al., later, also double-mutant modified HSV strain 3616UB was